Sprites
Freitag, 24.05.2013Börsentäglich über 11.000 News von 441 internationalen Medien
Erweiterte
Suche
Ad hoc-Mitteilungen

TROVAGENE INC

WKN: A1JY4B  ISIN: US8972383090  Ticker-Symbol: XE7A 
Aktie:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TROVAGENE INC Chart 1 Jahr
1-Woche-Intraday-Chart
TROVAGENE INC 1-Woche-Intraday-Chart
Aktuelle News zur TROVAGENE Aktie
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
15.05.-
14.05.46
SAN DIEGO, May 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months ended March 31, 2013....
Mehr lesen zu:
Trovagene, Inc. Announces First Quarter 2013 Earnings
06.05.30
NEW YORK, May 6, 2013 /PRNewswire/ --Today Highline Research Advisors initiated coverage through Empire Asset Management Company, a FINRA member (143007) of Trovagene (NASDAQ:TROV) with a BUY rating...
Mehr lesen zu:
Highline Research Advisors initiates coverage on Trovagene (NASDAQ:TROV) with a buy rating.
30.04.-
30.04.1
26.04.-
02.04.82
01.04.52
SAN DIEGO, April 1, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three months and the year ended...
Mehr lesen zu:
Trovagene, Inc., Announces Fourth Quarter and Year End 2012 Earnings
01.04.-
28.03.-
27.03.-
27.03.42
SAN DIEGO, March 27, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), today announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus (HPV)...
Mehr lesen zu:
Trovagene Launches Urine-Based HPV Test
12.03.35
SAN DIEGO, March 12, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni is scheduled...
Mehr lesen zu:
Trovagene to Present at 25th Annual Roth Conference
04.03.34
SAN DIEGO, March 4, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today announced that Mark Erlander, Ph.D., has joined the company as chief scientific...
Mehr lesen zu:
Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer
01.03.-
12.02.53
SAN DIEGO, Feb. 12, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV) today announced that the development of its proprietary, urine-based HPV carrier screening test is progressing well...
Mehr lesen zu:
Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
06.02.30
SAN DIEGO, Feb. 6, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled...
Mehr lesen zu:
Trovagene to Present at Leerink Swan Global Healthcare Conference
18.01.1
03.01.65
SAN DIEGO, Jan. 3, 2013 /PRNewswire/ --Trovagene, Inc. (Nasdaq:TROV), a developerof transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with...
Mehr lesen zu:
Trovagene to Study Transrenal BRAF Mutations in Primary and Metastatic Cancers
27.12.75
SAN DIEGO, Dec. 27, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:TROV), a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health...
Mehr lesen zu:
Trovagene, Inc., Grants License for NPM1 Marker for Acute Myelogenous Leukemia to Leading Academic Medical Center
Seite: 1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
Aufklappen
Schliessen